(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 12.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Rigel Pharmaceuticals's revenue in 2025 is $179,278,000.On average, 3 Wall Street analysts forecast RIGL's revenue for 2025 to be $3,556,568,527, with the lowest RIGL revenue forecast at $3,417,183,865, and the highest RIGL revenue forecast at $3,667,443,907. On average, 4 Wall Street analysts forecast RIGL's revenue for 2026 to be $4,081,632,314, with the lowest RIGL revenue forecast at $3,895,553,881, and the highest RIGL revenue forecast at $4,265,674,370.
In 2027, RIGL is forecast to generate $4,519,507,004 in revenue, with the lowest revenue forecast at $4,298,006,324 and the highest revenue forecast at $4,783,700,152.